



NEWS RELEASE

# Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

3/9/2021

BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.

---

Conference Call & Webcast Details  
Date: Thursday, March 25, 2021  
Time: 4:30 pm Eastern Time  
Domestic: 877-407-0789  
International: 201-689-8562  
Conference ID: 13717079  
Webcast: <https://investors.viridiantherapeutics.com/events/default.aspx>

A live webcast of the conference call can be accessed in the Investors section of Viridian Therapeutics website at <https://investors.viridiantherapeutics.com>

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes

inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids Viridian is headquartered in Boulder, Colorado, with additional operations in Waltham, Massachusetts. Learn more about Viridian and our programs at [www.viridiantherapeutics.com](http://www.viridiantherapeutics.com).

Follow us on Twitter @ViridianThera and on LinkedIn.

Contacts:

Investors

Dan Ferry

LifeSci Advisors

617-430-7576

**IR@viridiantherapeutics.com**

Media

Darby Pearson

Verge Scientific Communications

703-587-0831

**PR@viridiantherapeutics.com**

Source: Viridian Therapeutics, Inc.